Psychotropic drug prescription patterns among patients with bipolar I disorder

Bipolar Disorders

Volumn 2, Issue 2, 2000, Pages 120-130

  Levine, Joseph ^a,b,c   Chengappa, Roy ^a,b,c   Brar, Jaspreet S ^a   Gershon, Samuel ^a,c   Yablonsky, Eric ^a,c   Stapf, Deborah ^a,c   Kupfer, David J ^a,c  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b Mayview State Hospital   (United States)

^c Stanley Ctr Innov Treatm B   (United States)

Author keywords

Antidepressive agents; Antipsychotic agents; Bipolar disorder; Carbamazepine; Demography; Drug therapy combination; Lithium; Valproic acid

Indexed keywords

PSYCHOTROPIC AGENT;

ADULT; AGED; ARTICLE; BIPOLAR DISORDER; CLINICAL PRACTICE; DRUG COMBINATION; DRUG UTILIZATION; FEMALE; HUMAN; MALE; MIDDLE AGED; OUTPATIENT; REGISTER; RETROSPECTIVE STUDY; STATISTICS; UNITED STATES;

ADULT; AGED; BIPOLAR DISORDER; DRUG THERAPY, COMBINATION; DRUG UTILIZATION; FEMALE; HUMANS; MALE; MIDDLE AGED; OUTPATIENTS; PENNSYLVANIA; PHYSICIAN'S PRACTICE PATTERNS; PSYCHOTROPIC DRUGS; REGISTRIES; RETROSPECTIVE STUDIES;

EID: 0034208202     PISSN: 13985647     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-5618.2000.020205.x     Document Type: Article

References (73)

1. Sachs GS. Bipolar mood disorders: practical strategies for acute and maintenance phase treatment. J Clin Psychopharmacol 1996; 16 (Suppl 1): 32S-47S.
2. Post RM, Frye MA, Leverich GH, Denicoff KD. The role of complex combination therapy in the treatment of refractory bipolar illness. CNS Spectr 1998; 3: 66-86.
3. Anonymous. Practice guideline for the treatment of patients with bipolar disorder. American Psychiatric Association. Am J Psychiatry 1994; 151 (Suppl 12): 1-36.
4. Frances AJ, Docherty JP, Kahn DA. The expert consensus guideline series: treatment of bipolar disorder. J Clin Psychiatry 1996; 57 (Suppl 12A): 1-88.
5. American Psychiatric Association. Practice Guidelines for the Treatment of Patients with Bipolar Disorder. Wasington, DC: American Psychiatric Press, 1994.
6. Kusumakar V, Yatham LN. The treatment of bipolar disorder: review of the literature, guidelines, and options. Can J Psychiatry 1997; 42 (Suppl 2): 67S-100S.
7. Bauer MS, Callahan AM, Jampala C, Petty F, Sajatovic M, Schaefer V, Wittlin B, Powell BJ. Clinical practice guidelines for bipolar disorder from the Department of Veterans Affairs. J Clin Psychiatry 1999; 60: 9-21.
8. Gilbert DA, Altschuler KZ, Rago WV, Shon SP, Crismon ML, Toprac MG, Rush AJ. Texas medication algorithm project: definitions, rationale, and methods to develop medication algorithms. J Clin Psychiatry 1998; 59: 345-351.
9. Linden M. Individual aspects of physician and patient, and their impact on the prescription of psychotropic medication. Pharmacopsychiatry 1988; 21: 266-267.
10. Hemminki E. Polypharmacy among psychiatric patients. Acta Psychiatrica Scandinavica 1977; 56: 347-356.
11. Sheppard C, Collins L, Fiorentino D, Fracchia J, Merlis S. Polypharmacy in psychiatric treatment: I. Incidence at a state hospital. Curr Ther Res Clin Exp 1969; 11: 765-774.
12. Olfson M, Klerman GL. Trends in the prescription of antidepressants by office-based psychiatrists. Am J Psychiatry 1993; 150: 571-577.
13. Olfson M, Marcus SC, Pincus HA, Zito JM, Thompson JW, Zarin DA. Antidepressant prescribing practices of outpatient psychiatrists. Arch Gen Psychiatry 1998; 55: 310-316.
14. Bjerrum L, Sogaard J, Hallas J, Kragstrup J. Polypharmacy: correlations with sex, age and drug regimen. A prescription database study. Eur J Clin Pharmacol 1998; 54: 197-202.
15. Tachev T. The course and prognosis of depression on the basis of 652 patients deceased. In: Classification and Prediction of Outcome of Depression (Symposia Medica Hoechst). Stuttgart, New York: Schattauer Verlag, 1973; 157-172.
16. Zis AP, Grof P, Webster MA, Goodwin FK. The cyclicity of affective disorders and its modification by drugs. Prediction of relapse in recurrent affective disorder. Psychopharmacol Bull 1980; 16: 47-49.
17. Roy-Byrne R, Post RM, Uhde TW, Porcu T, Davis D. The longitudinal course of recurrent affective illness: life chart data from research patients at the NIMH. Acta Psychiatrica Scandinavica 1985; 71 (Suppl 317): 1-34.
18. Gotlin MJ, Swenden J, Heller TL, Hammen C. Relapse and impairment in bipolar disorder. Am J Psychiatry 1995; 152: 1635-1640.
19. Kessing LV. Recurrence in affective disorder: II. Effect of age and gender. Br J Psychiatry 1998; 172: 29-34.
20. Goodwin FK, Jamison KR. Manic-Depressive Illness. New York: Oxford University Press, 1990; 68-69, 703, 746-762.
21. Leinbenluft E. Women with bipolar illness: clinical and research issues. Am J Psychiatry 1996; 153: 163-173.
22. Krauthammer C, Klerman GL. The epidemiology of mania. In: Shopsin B, ed. Manic Illness. New York: Raven Press, 1979; 11-28.
23. Cluss PA, Marcus SC, Kelleher KJ, Thase M, Arvay LA, Kupfer DJ. Diagnostic certainty of a voluntary bipolar disorder case registry. J Affect Dis 1999; 52: 93-99.
24. First MB, Spitzer RL, Gibbon M, Williams JBW. Structured Clinical Interview for DSM-IV Axis I Disorders -Patient Edition. New York: New York State Psychiatric Institute, 1995.
25. Dunner DL, Gershon ES, Goodwin FK. Heritable factors in the severity of affective illness. Biol Psychiatry 1976; 11: 31-42.
26. Coryell W, Endicott J, Reich T, Andreasen N, Keller M. A family study of bipolar II disorder. Br J Psychiatry 1984; 145: 49-54.
27. Sadovnick AD, Remick RA, Lam R, Zis AP, Yee IM, Haggins MJ, Baird PA. Mood disorders service genetic database: Morbidity risks for mood disorders in 3942 first-degree relatives of 671 index cases with single depression, recurrent depression, bipolar I or bipolar II. Am J Med Genet 1994; 54: 132-140.
28. Kato T, Shioiri T, Murashita J, Hamakawa H, Inubushi T, Takahashi S. Phosphorus-31 magnetic resonance spectroscopy and ventricular enlargement in bipolar disorder. Psychiatry Res 1994; 55: 41-50.
29. Akiskal HS. Dysthymic and cyclothymic depressions: therapeutic considerations. J Clin Psychiatry 1994; 55 (Suppl): 46-52.
30. von Zerssen D, Tauscher R, Possl J. The relationship of premorbid personality to subtypes of an affective illness. A replication study by means of an operationalized procedure for the diagnosis of personality structures. J Affect Disord 1994; 32: 61-72.
31. Vieta E, Gasto C, Otero E, Nieto E, Vallejo J. Differential features between bipolar I and bipolar II disorders. Compr Psychiatry 1997; 38: 98-101.
32. Howland RH. Pharmacotherapy of inpatients with bipolar depression. Ann Clin Psychiatry 1997; 9: 199-202.
33. Tsuang MT, Woolson RF, Fleming JA. Premature deaths in schizophrenia and affective disorders: an analysis of survival curves and variables affecting a shortened survival. Arch Gen Psychiatry 1980; 37: 979-983.
34. Weeke A, Vaeth M. Excess mortality of bipolar and unipolar manic depressive patients. J Affect Disord 1989; 11: 227-234.
35. Sharma R, Marker HR. Mortality in affective disorder. J Affect Disord 1994; 31: 91-96.
36. Kessler RC, Rubinow DR, Holmes C, Abelson JM, Zhao S. The epidemiology of DSM-III-R bipolar I disorder in a general population survey. Psychol Med 1997; 27: 1079-1089.
37. Lish JD, Dime-Meenan S, Whybrow PC, Price RA, Hirschfeld RM. The National Depressive and Manic-Depressive Association (DMDA) survey of bipolar members. J Affect Disord 1994; 31: 281-294.
38. Kapur S, Ganguli R, Ulrich R, Raghu U. Use of random-sequence riboflavin as a marker of medication compliance in chronic schizophrenics. Schizophr Res 1991; 6: 49-53.
39. Weissman MM, Livingston BM, Leaf PJ, Florio LP, Holzer C. Affective disorders. In: Robins LN, Reiger DA, eds. Psychiatric Disorders in America. The Epidemiology Catchment Area Study. New York: The Free Press, 1991; 53-80.
40. Harrow M, Goldberg JF, Grossman LS, Meltzer HY. Outcome in manic disorders: a naturalistic follow-up study. Arch Gen Psychiatry 1990; 47: 665-671.
41. Sachs G, Lafer B, Truman CJ, Noeth M, Thibault AB. Lithium monotherapy: miracle, myth and misunderstanding. Psychiatric Ann 1994; 24: 299-306.
42. Vonig W, Rissom R, Kalfoglu G, Stein A, Reimer F. Long-term therapy of affective disorders: monotherapy or polypharmacy. Pharmacopsychiatry 1988; 21: 272-273.
43. Silverstone T, McPherson H, Hunt N, Romans S. How effective is lithium in the prevention of relapse in bipolar disorder? A prospective naturalistic follow-up study. Aust NZ J Psychiatry 1998; 32: 61-66.
44. Post RM, Denicoff KD, Leverich GS, Frye MA. Drug-induced switching in bipolar disorder: epidemiology and therapeutic implications. CNS Drugs 1997; 8: 352-365.
45. Altshuler LL, Post RM, Leverich GS, Mikalauskas K, Rosoff A, Ackerman L. Antidepressant-induced mania and cycle acceleration: a controversy revisited. Am J Psychiatry 1995; 152: 1130-1138.
46. Markar HR, Mander AJ. Efficacy of lithium prophylaxis in clinical practice. Br J Psychiatry 1989; 155: 496-500.
47. Maj M, Pirozzi R, Magliano L, Bartoli L. Long-term outcome of lithium prophylaxis in bipolar disorder: a 5-year prospective study of 402 patients at a lithium clinic. Am J Psychiatry 1998; 155: 30-35.
48. Kleiner J, Altshuler L, Hendrick V, Hershman JM. Lithium-induced subclinical hypothyroidism: review of the literature and guidelines for treatment. J Clin Psychiatry 1999; 60: 249-255.
49. Sachs GS, Lafer B, Stoll AL, Banov M, Thibault AB, Tohen M, Rosenbaum JF. A double-blind trial of buproprion versus desipramine for bipolar depression. J Clin Psychiatry 1994; 55: 391-393.
50. Zarate CA Jr, Tohen M, Baraibar G, Kando JC, Mirin J. Prescribing trends of antidepressants in bipolar depression. J Clin Psychiatry 1995; 56: 260-264.
51. Himmelhoch JM, Thase ME, Mallinger AG, Houck P. Tranylcypromine versus imipramine in anergic bipolar depression. Am J Psychiatry 1991; 148: 910-916.
52. Thase ME, Mallinger AG, McKnight D, Himmelhoch JM. Treatment of imipramine-resistant recurrent depression: IV. A double-blind crossover study of tranylcypromine for anergic bipolar depression. Am J Psychiatry 1992; 149: 195-198.
53. Sernyak MJ, Woods SW. Chronic neuroleptic use in manic-depressive illness. Psychopharmacol Bull 1993; 29: 375-381.
54. Sernyak MJ, Griffin RA, Johnson RM, Pearsall HR, Wexler BE, Woods SW. Neuroleptic exposure following inpatient treatment of acute mania with lithium and neuroleptic. Am J Psychiatry 1994; 151: 133-135.
55. Keck PE, McElroy SL, Strakowski SM, Balistreri TM, Kizer DI, West SA. Factors associated with maintenance antipsychotic treatment of patients with bipolar disorder. J Clin Psychiatry 1996; 57: 147-151.
56. Mukherjee S, Rosen AM, Caracci G, Shukla S. Persistent tardive dyskinesia in bipolar patients. Arch Gen Psychiatry 1986; 43: 342-346.
57. Kane JM. Tardive dyskinesia in affective disorders. J Clin Psychiatry 1999; 60 (Suppl 5): 43-47.
58. Segal J, Berk M, Brook S. Risperidone compared with both lithium and haloperidol in mania: a double-blind randomized controlled trial. Clin Neuropharmacol 1998; 21: 176-180.
59. Olanzapine HGEH Study Group, Tohen M, Sanger TM, McElroy SL, Tollefson GD, Chengappa KNR, Daniel DG, Petty F, Centorrino F, Wang R, Grundy SL, Greaney MG, Jacobs TG, David SR, Toma V. Olanzapine versus placebo in the treatment of acute mania. Am J Psychiatry 1999; 156: 702-709.
60. Calabrese JR, Kimmel SE, Woyshville MJ, Rapport DJ, Faust CJ, Thompson PA, Meltzer HY. Clozapine for treatment-refractory mania. Am J Psychiatry 1996; 153: 759-764.
61. Suppes T, Webb A, Paul B, Carmody T, Kraemer H, Rush AJ. Clinical outcome in a randomized 1-year trial of clozapine versus treatment as usual for patients with treatment-resistant illness and history of mania. Am J Psychiatry 1999; 156: 1164-1169.
62. Suppes T, Phillips KA, Judd CR. Clozapine treatment of nonpsychotic rapid cycling bipolar disorder: a report of three cases. Biol Psychiatry 1994; 36: 338-340.
63. Zarate CA, Tohen M, Baldessarini RJ. Clozapine in severe mood disorders. J Clin Psychiatry 1995; 56: 411-417.
64. Frye MA, Ketter TA, Altshuler LL, Denicoff K, Dunn RT, Kimbrell TA, Cora-Locatelli G, Post RM. Clozapine in bipolar disorder: treatment implications for other atypical antipsychotics. J Affect Disord 1998; 48: 91-104.
65. Busch FN, Miller FT, Weiden PJ. A comparison of two adjunctive treatment strategies in acute mania. J Clin Psychiatry 1989; 50: 453-455.
66. Sachs GS. Use of clonazepam for bipolar affective disorder. J Clin Psychiatry 1990; 51 (Suppl 5): 31-34.
67. Chouinard G, Young SN, Annable L. Antimanic effect of clonazepam. Biol Psychiatry 1983; 18: 451-466.
68. Edwards R, Stephenson U, Flewett T. Clonazepam in acute mania: a double-blind trial. Aust NZ J Psychiatry 1991; 25: 238-242.
69. Denicoff KD, Smith-Jackson EE, Disney ER, Ali SO, Leverich GS, Post RM. Comparative prophylactic efficacy of lithium, carbamazepine, and the combination in bipolar disorder. J Clin Psychiatry 1997; 58: 470-478.
70. Maj M, Pirozzi R, Kemali D. Long-term outcome of lithium prophylaxis in patients initially classified as complete responders. Psychopharmacology (Berlin) 1989; 98: 535-538.
71. Faedda AL, Tondo L, Baldessarini RJ, Suppes T, Tohen M. Outcome after rapid versus gradual discontinuation of lithium treatment in bipolar disorders. Arch Gen Psychiatry 1993; 50: 448-455.
72. Suppes T, Baldessarini RJ, Faedda AL, Tohen M. Risk of recurrence following discontinuation of lithium treatment in bipolar disorder. Arch Gen Psychiatry 1991; 48: 1082-1088.
73. Coryell W, Solomon D, Leon AC, Akiskal HS, Keller MB, Scheftner WA, Mueller T. Lithium discontinuation and subsequent effectiveness. Am J Psychiatry 1998; 155: 895-898.